New Independent Thermobalancing Treatment with Therapeutic Device for Chronic Prostatitis/Chronic Pelvic Pain Syndrome

Medications, alternative and complementary treatments for type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) are used frequently. The aim of this article is to define thermobalancing therapy as an independent treatment for internal diseases, such as CP/CPPS.
The effect of thermobalancing therapy (TT) by using Dr. Allen’s therapeutic device-(DATD) on patients with CP/CPPS was investigated. National institute of health chronic prostatitis symptom index (NIH-CPSI) scores, prostatic volume (PV), and maximum urinary flow rate (Qmax) were measured in one group of 45 patients who underwent TT and a control group that did not have TT. These all parameters were compared between groups.
No significant difference was found at baseline evaluation in treatment and control groups with regard to age, NIH-CPSI score, PV or Qmax. In the treatment group pain score decreased and quality of life (QoL) improved significantly, whereas in the control group no changes. TT reduced PV and increased Qmax significantly, whereas in the control group TT did not elicit significant changes in PV and Qmax.
The study has explored that TT with DATD as monotherapy for CP/CPPS patients: (i) reduces pain dramatically and improves QoL; (ii) reduces PV and increases Qmax. None of the patients who received TT suffered side effects and the cost of TT compares favourably with the cost of conventional treatment. Thus, TT could be recommended as a new independent treatment for CP/CPPS.